Ryvu Showcases PRMT5 Inhibitor Data at 2025 AACR-NCI-EORTC

Ryvu Therapeutics (WSE: RVU), a clinical-stage drug discovery and development company focusing on novel therapies that address emerging targets in oncology, is presenting preclinical data on RVU305 (PRMT5i) and the ONCO Prime Platform at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, October 22-26, 2025, in Boston, MA.

"We are excited to share new data that underscores the strength and breadth of Ryvu’s novel targets platform - ONCO Prime. Our preclinical findings demonstrate how rational design and deep biological understanding can lead to differentiated therapeutic candidates such as RVU305, as well as novel discovery platforms that uncover cancer-specific vulnerabilities. These advances reinforce our commitment to developing precision medicines that address significant unmet needs in oncology.”  said Krzysztof Brzózka, Ph.D., Chief Scientific Officer of Ryvu Therapeutics.

Details on the poster presentations are as follows:

Poster Title: “RVU305, a brain-penetrant MTA-cooperative PRMT5 inhibitor, shows efficacy in GBM preclinical models”Poster Number: B037Session date and time: Friday, October 24, 12:30 PM - 4:00 PM EST

RVU305, a potentially best-in-class, brain-permeable MTA-cooperative PRMT5 inhibitor, demonstrates significant promise in the treatment of MTAP-deleted cancers. Preclinical studies show that RVU305 selectively inhibits PRMT5 activity in MTAP-deleted cells, inducing a strong synthetic lethal effect while sparing regular counterparts. Mechanistically, RVU305 causes a dose-dependent reduction in SDMA-modified proteins, validating PRMT5 inhibition at the molecular level. Moreover, RVU305 delivers selective inhibition of PRMT5 in MTAP-deleted tumor cells. Its BID oral dosing and MTA-cooperative mechanism enable potent, on-target tumor inhibition while sparing healthy tissue. This translates into >100% tumor growth inhibition and multiple complete responses in MTAP-deleted models.

RVU305 demonstrates potent antiproliferative activity across multiple MTAP-deleted glioblastoma (GBM) cell lines with minimal effects on MTAP wild-type lines.  In vivo, RVU305 showed significant tumor growth inhibition (TGI) and good tolerability in an orthotopic U87-LUC glioblastoma mouse model. RVU305 demonstrated CNS penetration with predicted efficacious exposure in the brain of cynomolgus monkeys. Kp,uu modeling indicates brain target coverage significantly superior to clinical stage comparator.

Together, these findings position RVU305 as a promising therapeutic candidate capable of delivering targeted, brain-penetrant efficacy for MTAP-deleted gliomas, addressing a critical unmet medical need in GBM treatment. GLP toxicology studies for RVU305 have been completed with no major toxicology findings and favorable safety profile which supports planned completion of IND/CTA-enabling studies in Q4 2025.

Ryvu Therapeutics S.A. has received the European Union grant for the phased implementation of the project “New targeted therapy for tumors with MTAP gene deletion – Phase II”. The EU funding for Phase II will span 2023-2028 under grant agreement no.: FENG.01.01-IP.01-1012/23.

Also Read: CDSCO Launches ONDLS to Track High-Risk Pharma Solvents

Poster Title: “Identification of novel molecular vulnerabilities in colorectal cancer through integrated transcriptomic profiling and functional genomics”Poster Number: B050Session date and time:  Friday, October 24, 12:30 PM - 4:00 PM EST

This study describes the development of a comprehensive discovery platform designed to identify synthetic lethal (SL) interactions linked to major oncogenic drivers in colorectal cancer (CRC), including APC, KRAS, and SMAD4. By combining CRISPR-based functional screening with genomic and transcriptomic analyses across human intestinal stem cell (hISC)-derived isogenic models, patient-derived cells (PDCs), and clinical tumor specimens, the team uncovered novel molecular vulnerabilities specific to genetically defined CRC subtypes. Machine learning applied to RNA sequencing data enabled precise molecular subtyping and validation of model fidelity, while candidate targets were selected based on therapeutic relevance and selectivity for cancer cells. Through this integrated approach, three categories of actionable targets were identified:

• first-in-class synthetic lethal targets currently under active drug discovery and optimization,
• next-wave novel dependencies representing promising directions for future oncology programs,
• novel indications for FDA-approved drugs supporting opportunities for drug repurposing.

Together, these findings establish a robust framework for precision oncology, supporting the discovery of new targeted therapies for CRC and offering broad applicability to other cancer types.